Cargando…

Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index

BACKGROUND: The National Cancer Institute Moonshot research initiative calls for improvements in the analysis and reporting of treatment toxicity to advise key stakeholders on treatment tolerability and inform regulatory and clinical decision making. This study illustrates alternative approaches to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gresham, Gillian, Diniz, Márcio A, Razaee, Zahra S, Luu, Michael, Kim, Sungjin, Hays, Ron D, Piantadosi, Steven, Tighiouart, Mourad, Yothers, Greg, Ganz, Patricia A, Rogatko, André
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735773/ https://www.ncbi.nlm.nih.gov/pubmed/32091598 http://dx.doi.org/10.1093/jnci/djaa028

Ejemplares similares

On the properties of the toxicity index and its statistical efficiency
por: Razaee, Zahra S., et al.
Publicado: (2020)

Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30
por: Henry, N. Lynn, et al.
Publicado: (2022)

Visualizing adverse events in clinical trials using correspondence analysis with R-package visae
por: Diniz, Márcio A., et al.
Publicado: (2021)

Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
por: Calsavara, Vinicius F., et al.
Publicado: (2023)

Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35
por: Henry, N. Lynn, et al.
Publicado: (2021)

Simulation study comparing analytical methods for single-item longitudinal patient-reported outcomes data
por: Calsavara, Vinicius F., et al.
Publicado: (2022)

Comparison between continuous and discrete doses for model based designs in cancer dose finding
por: Diniz, Márcio Augusto, et al.
Publicado: (2019)

A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades
por: Diniz, Márcio A, et al.
Publicado: (2020)

A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials
por: Tighiouart, Mourad, et al.
Publicado: (2016)

Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding
por: Rogatko, André, et al.
Publicado: (2015)

Escalation with Overdose Control Using Time to Toxicity for Cancer Phase I Clinical Trials
por: Tighiouart, Mourad, et al.
Publicado: (2014)

Health‐related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R‐04
por: Ganz, Patricia A., et al.
Publicado: (2022)

The Integrated Web Portal for Escalation with Overdose Control (EWOC)
por: Wang, Haibin, et al.
Publicado: (2013)

caGrid-Enabled caBIG(TM) Silver Level Compatible Head and Neck Cancer Tissue Database System
por: Wang, Haibin, et al.
Publicado: (2010)

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

Update on the clinical trial landscape: analysis of ClinicalTrials.gov registration data, 2000–2020
por: Gresham, Gillian, et al.
Publicado: (2022)

Drug‐eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial
por: Rogatko, Cleo P., et al.
Publicado: (2021)

Epigenome overlap measure (EPOM) for comparing tissue/cell types based on chromatin states
por: Li, Wei Vivian, et al.
Publicado: (2016)

Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group
por: Ganz, Patricia A., et al.
Publicado: (2009)

Effect of Androgen Deprivation on Long-term Outcomes of Intermediate-Risk Prostate Cancer Stratified as Favorable or Unfavorable: A Secondary Analysis of the RTOG 9408 Randomized Clinical Trial
por: Zumsteg, Zachary S., et al.
Publicado: (2020)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials
por: George, Thomas J., et al.
Publicado: (2015)

Cardiac Telehealth Pre-Admission Clinic at a Tertiary Hospital – Impact on Patient Journey During the COVID-19 Pandemic
por: Lau, J., et al.
Publicado: (2022)

The 24-Hour Movement Paradigm: An integrated approach to the measurement and promotion of daily activity in cancer clinical trials
por: Shirazipour, Celina H., et al.
Publicado: (2023)

Microcystin uptake and biochemical responses in the freshwater clam Corbicula leana P. exposed to toxic and non-toxic Microcystis aeruginosa: Evidence of tolerance to cyanotoxins
por: Pham, Thanh-Luu, et al.
Publicado: (2015)

Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients
por: Gresham, Gillian, et al.
Publicado: (2018)

Improving the tolerability of osimertinib by identifying its toxic limit
por: Agema, Bram C., et al.
Publicado: (2022)

Benefits of nature-based walking for breast cancer survivors
por: Shirazipour, Celina H, et al.
Publicado: (2023)

A 6-Week Program to Strengthen Resiliency Among Women With Metastatic Cancer: A Randomized Clinical Trial
por: Asher, Arash, et al.
Publicado: (2023)

Glucocorticoid toxicity reduction with mepolizumab using the Glucocorticoid Toxicity Index
por: McDowell, P. Jane, et al.
Publicado: (2022)

Assessment of Trends in the Design, Accrual, and Completion of Trials Registered in ClinicalTrials.gov by Sponsor Type, 2000-2019
por: Gresham, Gillian, et al.
Publicado: (2020)

Understanding physical activity in cancer patients and survivors: new methodology, new challenges, and new opportunities
por: Schrack, Jennifer A., et al.
Publicado: (2017)

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies
por: Harvey, R D, et al.
Publicado: (2013)

Multidrug-Resistance and Toxic Metal Tolerance of Medically Important Bacteria Isolated from an Aquaculture System
por: Resende, Juliana Alves, et al.
Publicado: (2012)

Copy number variation alters local and global mutational tolerance
por: Avecilla, Grace, et al.
Publicado: (2023)

Metallothionein in the extracellular fluids as an index of cadmium toxicity.
por: Shaikh, Z A, et al.
Publicado: (1979)

Occurrence of Multidrug-Resistant and Toxic-Metal Tolerant Enterococci in Fresh Feces from Urban Pigeons in Brazil
por: da Silva, Vânia Lúcia, et al.
Publicado: (2012)

Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity
Publicado: (1988)

Rechallenge of voriconazole successfully tolerated after hepatic toxicity
por: Narumoto, O., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pl5vb11jmufqdis6us9f93b65m